Table 2.
Overview of studies using TARE in patients with BCLM
| Authors, year | Number of patients, n | Type of microspheresa (mean activityb) | Assessment criteriac | Complete response, % | Partial response, % | Stable disease, % | Progressive disease, % | Median survival, months | Mean survival, months |
|---|---|---|---|---|---|---|---|---|---|
| Bangash et al., 2007 [34] | 27 | glass (2.05 ±1.06 GBq) | WHO | 39 | 39 | 52 | 8.8 | nr | nre |
| Jakobs et al., 2008 [17] | 30 | resin (1.896 GBq) | RECIST | 0 | 61 | 35 | 4 | 11.7 (significantly better for patients with CR or PRd) | 9.6 |
| Haug et al., 2012 [35] | 58 | resin (1.77 ± 0.49 GBq) | RECIST | 0 | 25.6 | 62.8 | 11.6 | 6.7 | nr |
| Gordon et al., 2014 [36] | 75 | glass (1.52 GBq) | RECIST | 35.3 | 63.4 | 1.5 | 6.6 | nr | |
| Saxena et al., 2014 [37] | 40 | resin (1.67 ± 0.36 GBq) | RECIST | 5 | 26 | 39 | 29 | 13.6 | nr |
a
Glass = Glass microspheres (TheraSphere; BTG International Ltd, London, UK). Resin = Resin microspheres (SIR-Spheres; SIRTex Medical Limited, Sydney, Australia).
b
Mean activity infused during TARE. Data are displayed in gigabecquerel (GBq).
c
Assessment criteria of response. WHO = World Health Organization; RECIST = response evaluation criteria in solid tumors.
d
CR = Complete response; PR = partial response according to RECIST.
e
nr = Not reported.